Flyer
Viral Vector Packaging Test - Seamless Transition from Discovery to CMC
Viral Vector Packaging Test
Seamless Transition from Discovery to CMC
In cell and gene therapy programs, early-stage decisions often carry long-term
implications—especially for vector design, process development, manufacturability, and
scalability. ProBio‘s packaging test aims to support the delivery of feasibility-level data and
technical confidence to inform next steps.
Multiple scenarios
Candidate selection
Sample preparation for pharmacology study
Feasibility test of ProBio’s proprietary packaging system and platform process
Fast turnaround time
3+ weeks fast delivery
Seamless transition from discovery to CMC
Same cell line and packaging plasmids used in CMC development
tLVV Packaging Test
AAV Packaging
Test
LVV Packaging Test
(target LVV for in vivo CAR - T)
PowerSTM-ITRrs
strain
Strain/Backbone
LentiBoneTM
LentiBoneTM
LentiBoneTM III-TC
LentiBoneTM III-TC
Packaging
Plasmid
LentiHelperTM
plasmids
LentiHelperTM
plasmids
LentiHelperTM
plasmids
LentiHelperTM
plasmids
AAssistVTM
plasmids
System
Cell Line
Adherent
Suspension
PowerSTM-293T
Bioreactor
Suspension
PowerSTM-293T
Shake flask
NA
Suspension
Suspension
PowerSTM-293
Shake flask
PowerATM-293T
Cell factory
PowerSTM-293T
Bioreactor
(DoE design)
Upstream
Downstream
Platform process
Platform process
Platform process
Platform process
Titer
Titer
Genome Purity
Full/empty ratio
Endotoxin
Titer
Titer
QC
Physical titer (p24)
Physical titer (p24)
Physical titer (p24)
Physical titer (p24)
Endotoxin
Endotoxin
ROA
LVV
ROA
LVV
ROA
ROA
LVV
ROA
AAV
Deliverable
TAT
Supernatant/condition
4~5 weeks
4~5 weeks
3 weeks
4~5 weeks
4~6 weeks
ProBioCDMO.com
+1-732-885-9188
Accelerating Ideas. Delivering Impact.
tLVV for in vivo CAR-T
Challenge: mutant envelope proteins cause fluctuations in LVV titer and aggregation
Case study: screening of 7 combinations reveals significant titer variations based on
Fusogen-Binder pairing
Harvest titer - FACS
6
5
4
3
2
1
0
Combination 1
Combination 2 Combination 3 Combination 4
Combination 5
Combination 6
Combination 7
Challenge: spatial hindrance between Binder and Fusogen reduces transduction efficiency
Case study: DoE (Design of Experiments) methodology systematically screens optimal ratios of the 5
plasmids (Transfer/Gagpol/Rev/Fusogen/Binder) during packaging testing. Identifying sufficient
targeting molecules without over-expression hindering fusion—to maximize transduction
efficiency.
P24/FACS ratio
Harvest titer- FACS
1
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
DOE group
1
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
DOE group
Harvest titer- P24
FACS
P24
Desirability
Binder Desirability
Transfer
Gag/pol
Rev
Fusogen
1
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
DOE group